Company intelligence / Profile preview
CiRC Biosciences
Chicago, Illinois, United Statescircbiosciences.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Preclinical
01
Overview
CiRC Biosciences is advancing a pre-clinical program using chemically induced cellular reprogramming to restore vision in models of Dry AMD and RP. Preclinical studies have shown efficacy in blind mice with demonstrated vision restoration. No FDA-approved treatments currently exist for these indications[5].
- Therapeutic areas
- Ophthalmology
- Modalities
- Cell therapy (cellular reprogramming)Small molecules (for direct cell conversion)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Paragon Biosciences
Beyond the preview
Go deeper on CiRC Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CiRC Biosciences.